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ORIGINAL ARTICLE
A Fixed Ratio Combination of Insulin Degludec and
Liraglutide (IDegLira) Reduces Glycemic Fluctuation
and Brings More Patients with Type 2 Diabetes
Within Blood Glucose Target Ranges
Allen B. King, MD, 1 Athena Philis-Tsimikas, MD,2 Eric S. Kilpatrick, MBChB, MD,3
Irene H. Langbakke, MD,4 Kamilla Begtrup, MSc,4 and Tina Vilsbøll, MD, DMSc5
Abstract
Background: Reducing glycemic fluctuation is important for optimal diabetes management. This post hoc
analysis examined glycemic fluctuations and the proportion of subjects achieving recommended blood glucose
targets with the fixed ratio combination of insulin degludec and liraglutide (IDegLira) compared to insulin
degludec (IDeg) and liraglutide alone.
Methods: We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials
involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data
from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.
Results: Compared with IDeg, IDegLira resulted in a greater proportion of subjects with SMBG values within
target ranges (3.9–9.0mmol/L) than IDeg for all pre- and postprandial values, and for the full nine-point profile
(P< 0.05 for all). IDegLira also resulted in a greater reduction in the range of SMBG values over 24 h than IDeg
(P£ 0.0001). CGM data showed that IDegLira provided greater reductions in interstitial glucose (IG) fluctuation
(P= 0.0018) and postprandial IG increment (P= 0.0288) compared with IDeg. Compared with liraglutide,
IDegLira brought a higher proportion of subjects within SMBG target ranges (all pre- and all postprandial
values, and the full nine-point profile, P< 0.01 for all) and resulted in a greater reduction of time outside the IG
target range (P= 0.0072). IDegLira also reduced mean IG more than liraglutide (P< 0.0001).
Conclusions: Treatment with IDegLira allows more patients with T2D to maintain blood glucose within target
ranges throughout the day than either IDeg or liraglutide alone.
Keywords: Insulin degludec, Liraglutide, Type 2 diabetes, GLP-1 analog, Continuous glucose monitoring.
Introduction
Therapeutic aims in diabetes include achieving targetglycated hemoglobin (HbA1c) levels and reducing gly-
cemic fluctuations to achieve a balance between glycemic
control and avoidance of hypoglycemia.1,2 Unfortunately,
patients with an acceptable HbA1c level may still experience
significant glycemic fluctuation over a 24-h period.3 There is
evidence that glycemic fluctuation is an independent risk
factor for diabetic complications,4,5 predictive of hypogly-
cemia,6 and whenmanifesting as postprandial hyperglycemia
may contribute to vascular complications.7–9 Despite some
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controversy on these issues,10,11 reducing glycemic fluctua-
tion is important for optimal glycemic control,4 and treat-
ments that offer reductions in both HbA1c and glycemic
fluctuation are desirable.
IDegLira, a fixed ratio combination of insulin degludec
(IDeg), a long-acting basal insulin, and the glucagon-like
peptide-1 (GLP-1) receptor agonist, liraglutide, has demon-
strated significantly greater reductions in HbA1c compared to
the individual components liraglutide and IDeg alone.12–15
IDegLira has also been shown to have favorable effects on
body weight and reduced risk of hypoglycemia compared to
IDeg alone.12–15 These observations are likely explained by
the complementary mode of action of the two components of
IDegLira, namely the ability of IDeg to reduce fasting plasma
glucose16 and the glucose-dependent effects of liraglutide,
both lowers fasting plasma glucose and reduces postprandial
glucose excursions.17
The objective of this post hoc analysis was to use self-
monitored blood glucose (SMBG) and continuous glucose
monitoring (CGM) to determine whether or not IDegLira
would bring more patients with type 2 diabetes (T2D) within
blood glucose target ranges, compared to its individual com-
ponents. In this article, we describe glycemic fluctuation from
a patient’s average blood glucose values and explore day-to-
day variability by comparing the standard deviation (SD) of
consecutive blood glucose concentrations.
Materials and Methods
DUAL I extension and DUAL II study overviews
This post hoc analysis used data from the DUAL I extension
and DUAL II trials in patients with T2D; detailed trial designs
and methods were reported previously.13–15 Briefly, DUAL
I was a 26-week trial14 with an extension to 52 weeks15 com-
paring IDegLira with IDeg or liraglutide in insulin-naı¨ve
patients uncontrolled on oral antidiabetic drugs (OADs; in
this case being metformin with or without pioglitazone).
Throughout this article,when referring toDUAL I, results from
the full 52-week trial are reported. In DUAL II, IDegLira was
compared with IDeg for 26 weeks in patients who were pre-
viously uncontrolled on 20 to 40U of basal insulin plus met-
formin, with or without sulfonylureas or glinides; these latter
two classeswere discontinued at randomization.13 InDUAL II,
IDeg was limited to a maximum dose of 50U so that the
contribution of the liraglutide component of IDegLira could be
evaluated at equivalent insulin doses. The trial protocols were
approved by independent ethics committees or institutional
review boards at all participating institutions and conducted in
accordancewith the Declaration of Helsinki and GoodClinical
Practice guidelines.18,19 Written informed consent from all
patients was obtained before enrollment. The baseline char-
acteristics of the patients in the two trials are summarized in the
Supplementary Tables S1 and S2 (Supplementary Data are
available online at www.liebertpub.com/dia).
SMBG profiles
SMBG levels were assessed in the DUAL I extension
and DUAL II trials using hand-held glucose meters (Abbott
Diabetes Care, Alameda) calibrated to display plasma equiv-
alent values of capillary whole blood glucose measurements.
SMBG levels were recorded in the diary in the following se-
quence of time points: (1) just before breakfast; (2) 90min
after the start of breakfast; (3) just before lunch; (4) 90min
after the start of lunch; (5) just before dinner; (6) 90min after
the start of dinner; (7) at bedtime; (8) at 4 am; and (9) just
before breakfast the following day. These nine-point profiles
were completed within 1 week before site visits on a day when
the subject did not anticipate unusual strenuous exercise. The
90-min postprandial interval was selected as the mid-point in
the 1–2h timeframe recommended for assessing postprandial
plasma glucose targets, and in an effort to provide a closer
reflection of postprandial peak than the common 2-h post-
prandial interval.4,20 In addition, fasting prebreakfast SMBG
wasmeasured daily for both IDeg and IDegLira treated patients
(the two study arms that included dose titration), and 3 days a
week for liraglutide-treated patients (as per study protocol).
Interpreting nine-point SMBG profiles. We assessed the
proportions of patients treated with IDegLira, IDeg, or lir-
aglutide, who achieved SMBG values (plasma equivalent
values) from the nine-point profile within recommended cap-
illary plasma glucose target ranges at baseline and end-of-trial
(EOT).4,21 The preprandial (before breakfast, lunch, dinner,
and breakfast the following day) target was achieved if SMBG
was ‡3.9 and £7.2mmol/L at all four assessments.21 The
postprandial (90min after all three meals) target was SMBG
<9.0mmol/L at all three assessments.4 Patients were consid-
ered to have the entire nine-point profile within target range if
SMBG was ‡3.9 and <9.0mmol/L at all nine assessments (all
pre- and postprandial time points, before bedtime and 4 am).
We also assessed the range of SMBG values in the nine-
point profile (the difference between the minimum and max-
imum SMBG values recorded) for each individual patient, at
baseline and at EOT. The difference in range from baseline to
EOT was determined for each patient, and the change in range
was compared across treatments arms.
Analysis of parameters determined from the nine-point
profiles was based on the full analysis set (FAS; all ran-
domized subjects), with the last observation carried forward
(LOCF) method of imputation for all subjects with a full
nine-point profile at baseline. Continuous endpoints were
analyzed using an analysis of covariance (ANCOVA) model
with treatment, region, sub-study, baseline HbA1c stratum
(£8.3% [£67mmol/mol], >8.3% [>67mmol/mol]), and pre-
vious OAD treatment as fixed effects, and the baseline value
of the parameter included as a covariate. Binary endpoints
were analyzed using logistic regression with treatment, re-
gion, baseline HbA1c stratum (£8.3% [£67mmol/mol],
>8.3% [>67mmol/mol]), and previous OAD treatment as
fixed effects.
Day-to-day variability with prebreakfast SMBG values. The
coefficient of variation (CV, defined as the SD of the mea-
surements as a percentage of the mean) of prebreakfast
SMBG was calculated for each patient during the mainte-
nance period of treatment to assess day-to-day variability.
The maintenance period was defined as week 16 (inclusive)
onward, and covered 38 visits over 37 weeks in DUAL I
(weeks 16–52; includes regular and follow-up visits in week
27), and 11 visits over 11 weeks in DUAL II (weeks 16–26).
The CV of the individual prebreakfast SMBG values
during the maintenance period was log-transformed before
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analysis. Data were analyzed using an ANCOVAmodel with
treatment, region, sub-study, baseline HbA1c stratum (£8.3%
[£67mmol/mol], >8.3% [>67mmol/mol]), and previous OAD
treatment as fixed effects.
Continuous glucose monitoring
CGM was used to characterize interstitial glucose (IG)
excursions over a 24-h period encompassing all three main
meals, at baseline and at week 52, in the DUAL I extension
sub-study of 260 patients. Subjects wore the CGM device
(iPro1 and iPro2 [Europe and Australia], Medtronic Inter-
national, Tolochenaz, Switzerland) for a minimum of 72 h for
each recording, performed 3–4 days immediately before site
visits. IG measurements were recorded every 5min during
each 72-h period and calibration of CGM devices was com-
pleted, using SMBG values (methods described previously),
four times per day as per the manufacturer’s instructions.
Subjects were instructed to maintain diet, OAD dose, and
investigational product treatment dose during the 72-h pe-
riod. Subjects recorded meal times and dates in diaries during
CGM; meal times were confirmed by cross-checking against
rises in IG on the CGM profile. Successfully uploaded CGM
data were blind-reviewed and quality checked for missing
information, such as meal times. CGM data were not col-
lected in the DUAL II study.
We assessed the following CGM parameters: mean IG; IG
fluctuation (adjusted integrated absolute distance from the
mean profile, that is, flatness of IG profile; Formula S1); mean
amplitude of glycemic excursions (MAGE); low blood glu-
cose index (LBGI); high blood glucose index (HBGI); post-
prandial IG increment across all meals (90min after the start of
each meal—in line with the postprandial time point used for
the nine-point SMBG profiles); time spent with IG >3.9mmol/
L and £9.0mmol/L, as a measure of the time that glucose
profile was within range; duration and episodes (number of
times the profile goes below the threshold after having been
either above or missing) of IG <3.1 and <3.9mmol/L, including
during the nocturnal period (00:01–05:59); day-to-day IG var-
iability (SD of daily [24h] mean IG); and day-to-day variability
of fasting IG (SD of daily fasting IG, 20min before breakfast).
Objective decision rules were used to handle incomplete
CGM data. If there was no valid sensor value 5min before, or
85 to 95min after, the start of a meal, the meal increment was
considered missing. If this total interval included a 30min
continuous period without sensor values, the meal was con-
sidered missing. For incomplete profiles, mean IG and IG
fluctuation were derived from periods with available data.
All CGM parameters, except for episodes of IG <3.1 and
<3.9mmol/L, were analyzed based on observed data using an
ANCOVA model with treatment, region, baseline HbA1c
stratum (£8.3% [£67mmol/mol], >8.3% [>67mmol/mol]);
and previous OAD treatment as fixed effects, and baseline
values of parameters included as covariates for mean IG and
postprandial IG increment. The SD of daily mean and daily
fasting IG was log-transformed before analysis. Analysis of
the episodes of IG <3.1mmol/L and <3.9mmol/L was based
on observed data using a negative binomial regression model
with a log link and the logarithm of the profile duration as
offset, and treatment, region, baseline HbA1c stratum (£8.3%
[£67mmol/mol], >8.3% [>67mmol/mol]) and previous
OAD treatment as fixed effects.
Results
As described previously, baseline characteristics were well
matched across treatment groups in the DUAL I extension
(Supplementary Table S1)15 and DUAL II (Supplementary
Table S2) trials.13
SMBG profiles
Nine-point SMBG profiles. Nine-point SMBG profiles
were analyzed for all subjectswith a full profile at baseline: 90%
of subjects (FAS) in DUAL I extension15 and 95% in DUAL
II,13 respectively.
At baseline, the proportion of patients with SMBG values
(plasma equivalent values) within the target ranges was
similar across treatments in the two trials (2%–7%, Table 1).
At EOT, the proportion of patients with all three postprandial
SMBG measurements <9mmol/L was greater with IDegLira
versus IDeg (odds ratio [OR] 1.77, 95% confidence interval
[CI] 1.37 to 2.28, P < 0.0001) or liraglutide (OR 1.93, 95% CI
1.49 to 2.49, P< 0.0001) alone in DUAL I extension and
versus IDeg in DUAL II (OR 1.90, 95% CI 1.17 to 3.07,
P= 0.0093) (Table 1 and Supplementary Figs. S1 and S2;
Supplementary Data are available online at www.liebertpub.
com/dia). The proportion of patients with all four preprandial
SMBG measurements within target range (3.9–7.2mmol/L)
was also greater with IDegLira versus IDeg (OR 1.34, 95%
CI 1.05 to 1.72, P= 0.0204) or liraglutide (OR 2.06, 95% CI
1.59 to 2.67, P< 0.0001) alone in DUAL I extension and
versus IDeg in DUAL II (OR 2.29, 95% CI 1.41 to 3.73, P=
0.0008) (Table 1 and Supplementary Figs. S3 and S4). Simi-
larly, the proportion of patients with all nine SMBG mea-
surements within target range (‡3.9 and <9mmol/L) was
greater with IDegLira versus IDeg (OR 1.79, 95% CI 1.36 to
2.36, P< 0.0001) or liraglutide (OR 1.46, 95% CI 1.12 to 1.92,
P= 0.0059) alone in DUAL I extension and versus IDeg in
DUAL II (OR 2.07, 95% CI 1.22 to 3.49, P= 0.0067) (Table 1
and Supplementary Fig. S5).
The reduction in nine-point profile range (minimum–
maximum) from baseline to EOTwas statistically significantly
greater with IDegLira than with IDeg (DUAL I: estimated
treatment difference [ETD] -0.80mmol/L, 95% CI -1.08 to
-0.52, P< 0.0001; DUAL II: ETD -1.02mmol/L, 95% CI
-1.53 to-0.50,P= 0.0001), andwas similar between IDegLira
and liraglutide (ETD 0.01mmol/L, 95% CI -0.27 to 0.30,
P=NS) (Fig. 1).
Day-to-day variability with prebreakfast SMBG values.
There was no statistically significant difference in CV of pre-
breakfast SMBG in the maintenance period in DUAL I ex-
tension between IDegLira and IDeg (treatment ratio: 0.95, 95%
CI 0.90 to 1.00, P= 0.0638), but CV was statistically signifi-
cantly greater with IDegLira compared with liraglutide (treat-
ment ratio: 1.09, 95%CI 1.04 to 1.15,P= 0.0008). InDUAL II,
the CV of prebreakfast SMBG during the maintenance period
was statistically significantly lower with IDegLira than with
IDeg (treatment ratio: 0.88, 95% CI 0.81 to 0.97, P= 0.0091).
Continuous glucose monitoring
Baseline characteristics of subjects in the CGM sub-study
were well matched and similar to the full trial populations
(Table 2 and Supplementary Table S1).14,15 Due to subject
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FIG. 1. Nine-point SMBG{ profile{ showing calculation of range (a) and change from baseline to EOT in DUAL I and
DUAL II (b). {SMBG assessed with glucose meter as plasma equivalent values of capillary whole blood glucose. {Illustrative
example not intended to represent actual patients or treatment effects. Data are based on FAS, with LOCF for all subjects with a
full nine-point profile at baseline; P-values are from ANCOVA with treatment, region, baseline HbA1c stratum (£8.3%
[£67mmol/mol], >8.3% [>67mmol/mol]), and previous OAD treatment as fixed effects, and baseline value of the parameter
included as covariate. ANCOVA, analysis of covariance; EOT, end-of-trial; ETD, estimated treatment difference; FAS, full
analysis set; HbA1c, glycosylated hemoglobin; IDeg, insulin degludec; IDegLira, fixed ratio combination of insulin degludec
and liraglutide; Lira, liraglutide; LOCF, last observation carried forward; OAD, oral antidiabetic drug; NS, not significant;
SMBG, self-monitored blood glucose.
Table 2. DUAL I Extension Continuous Glucose Monitoring Sub-Study Baseline Characteristics
Characteristic IDegLira (n = 131) IDeg (n= 64) Liraglutide (n = 65)
Male/female, % 55/45 56/44 46/54
Age, years 54.4 (9.3) 55.0 (8.5) 55.0 (10.3)
BMI, kg/m2 32.5 (4.4) 32.4 (4.5) 32.3 (4.8)
Duration of diabetes, years 7.5 (5.7) 7.5 (4.9) 8.1 (5.1)
HbA1c, % 8.2 (0.9) 8.2 (0.9) 8.3 (1.0)
HbA1c, mmol/mol
a 66 (10) 66 (10) 67 (11)
FPG, mmol/L 9.2 (2.3) 9.1 (2.7) 9.2 (2.4)
Fasting C-peptide, nmol/L 0.79 (0.37)b 0.85 (0.48)c 0.81 (0.37)d
Values are mean (SD) unless otherwise stated.
aCalculated, not measured.
bn = 127.
cn = 62.
dn = 63.
BMI, body mass index; CGM, continuous glucose monitoring; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IDeg, insulin
degludec; IDegLira, fixed-ratio combination of insulin degludec and liraglutide; SD, standard deviation.
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withdrawal, site closure, and technical issues (primarily dif-
ficulties with insertion of the sensor and sites’ failure to ac-
tivate the devices), usable CGM data were not available from
a number of subjects (Supplementary Table S3). CGM
profiles were therefore missing from 20% of subjects at
baseline, and 38% at week 52; profiles were missing from
13% of subjects at both time points. CGM profiles were
missing from 45% at either baseline or week 52 visits (Sup-
plementary Table S3). Missing profiles due to site closure and
technical issues were considered missing completely at ran-
dom. Proportions of profiles missing due to withdrawal of
subjects were similar across treatment groups, and baseline
characteristics of patients in the sub-study with available
CGM data at week 52 (Supplementary Table S4) were well
matched and similar to those of the full DUAL I extension
trial population.15
In the DUAL I extension CGM sub-study, mean IG de-
creased more with IDegLira than with liraglutide (ETD
-1.0mmol/L, 95% CI -1.5 to -0.5, P < 0.0001); IDeg pro-
duced a similar reduction to IDegLira (ETD 0.0mmol/L,
95% CI -0.5 to 0.5, P = 0.9655) (Table 3). Statistically sig-
nificantly lower IG fluctuations (treatment ratio 0.8, 95% CI
0.7 to 0.9, P = 0.0018) and a greater reduction in postprandial
IG increments across all meals (ETD–0.5mmol/L, -0.9 to
-0.1, P = 0.0288) were observed with IDegLira versus IDeg
(Table 3). IG fluctuations and postprandial IG increments
were similar with IDegLira versus liraglutide (Table 3). Re-
sults were generally consistent across other measures of
glycemic fluctuation (MAGE, LBGI, HBGI); however, there
were no statistically significant differences between IDegLira
and IDeg for LBGI and HBGI (Supplementary Table S5).
From a similar distribution at baseline, more time was
spent within IG target range (3.9 to <9.0mmol/L) for all three
treatment groups at week 52 (Fig. 2). Time (hours/day) out-
side IG target range was statistically significantly lower with
IDegLira than with liraglutide (ETD–2.2 h/day, 95% CI -3.8
to -0.6, P = 0.0072), but there was no statistically significant
difference in time outside range between IDegLira and IDeg
(ETD–0.7 h/day, 95% CI -2.4 to 1.0, P = 0.4310). The du-
ration of IG <3.9 and <3.1mmol/L was similar in patients
treated with IDegLira compared to liraglutide or IDeg alone.
In contrast, the rate of episodes (number per 100 h) of IG
<3.9mmol/L with IDegLira was statistically significantly
lower than with IDeg (treatment rate ratio 0.6, 95% CI 0.4 to
1.0, P= 0.0357) and higher than with liraglutide (treatment
rate ratio 2.2, 95% CI 1.3 to 3.8, P = 0.0045). The rate of
episodes (number per 100 h) of IG <3.1mmol/L was similar
for IDegLira compared to liraglutide or IDeg alone (Fig. 2). A
similar pattern of results was observed for rates of episodes of
low IG (<3.9 and <3.1mmol/L) during the nocturnal period
(00:01–05:59), but low event numbers dictate that mean-
ingful statistical comparisons were not possible for nocturnal
episodes (Supplementary Table S6).
Day-to-day IG variability (SD of daily [24 h] mean) and
variability of fasting IG (20min before breakfast) was similar
with IDegLira, IDeg, or liraglutide (Table 3).
Discussion
In this post hoc analysis of two randomized, controlled
trials in T2D, data captured via nine-point SMBG profiles and
CGMwere utilized to more precisely characterize fluctuation
Table 3. Glycemic Fluctuation and Variability in Patients with Type 2 Diabetes Treated for 52 Weeks
in the DUAL I Extension Continuous Glucose Monitoring Sub-Study
CGM parameter
IDegLira
(n = 131)
IDeg
(n = 64)
ETD [95% CI]:
IDegLira vs. IDeg
Lira
(n= 65)
ETD [95% CI]:
IDegLira vs. Lira
Mean IG (mmol/L)
Mean at baseline 10.2 (2.2) 10.2 (2.1) 10.0 (2.5)
Mean D, w52 -3.5 (1.9) -3.6 (1.9) 0.0 [-0.5 to 0.5]
(P = 0.9655)
-2.5 (2.5) -1.0 [-1.5 to -0.5]
(P < 0.0001)
IG fluctuation (adjusted integrated absolute distance from the mean profile, i.e., flatness of IG profile, mmol/L)
Geometric mean at baseline 1.5 1.6 1.5
Geometric mean at w52 1.0 1.3 Ratio: 0.8 [0.7 to 0.9]
(P = 0.0018)
1.1 Ratio: 1.0 [0.8 to 1.1]
(P = 0.6681)
Postprandial IG increment across all meals (90min, mmol/L)
Mean at baseline 1.4 (1.3) 1.4 (1.8) 1.5 (1.2)
Mean D, w52 -0.5 (1.2) 0.2 (1.8) -0.5 [-0.9 to -0.1]
(P = 0.0288)
-0.2 (1.4) -0.2 [-0.6 to 0.2]
(P = 0.3039)
Day-to-day IG variability (SD of daily [24 h] mean, mmol/L)
Mean at baseline (SE) 0.8 (0.1) 1.0 (0.1) 0.8 (0.1)
Mean at w52 (SE) 0.6 (0.0) 0.6 (0.1) -0.1 [-0.2 to 0.1]
(P = 0.4197)
0.5 (0.1) 0.1 [-0.0 to 0.3]
(P = 0.1056)
Day-to-day variability of fasting IG, 20min before breakfast (SD of daily fasting IG, mmol/L)
Geometric mean at baseline (CV) 0.8 (115.4) 0.7 (130.4) 0.8 (127.5)
Geometric mean at w52 (CV) 0.6 (106.7) 0.5 (139.9) Ratio: 0.9 [0.6 to 1.3]
(P = 0.4811)
0.5 (121.1) Ratio: 0.8 [0.5 to 1.2]
(P = 0.2462)
Values are mean (SD) unless otherwise stated. CGMparameters are analyzed based on observed data using an ANCOVAmethod with treatment,
region, baseline HbA1c stratum (£8.3% [£67mmol/mol], >8.3% [>67mmol/mol]), and previous OAD treatment as fixed effects. Baseline values of
parameters were included as covariates for mean IG and postprandial IG increment. Fluctuation is log-transformed before analysis.
ANCOVA, analysis of covariance; CV, coefficient of variation; ETD, estimated treatment difference; IG, interstitial glucose; Lira,
liraglutide; SE, standard error; w, week.
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in daily blood glucose values, thereby allowing a more in-
depth evaluation of diabetes treatment. These new data
support the main trial findings and provide further evidence
that the complementary effects of IDeg and liraglutide al-
low more patients treated with IDegLira to achieve their
glycemic target.
The analysis of DUAL I extension CGM data showed that
treatment with IDegLira resulted in a greater reduction ofmean
IG compared to liraglutide, but not compared to IDeg. This is
consistent with the previously reported finding that IDegLira
reduced the mean nine-point profile significantly more than
liraglutide, but conferred a similar reduction to IDeg.15 The
present analysis of the nine-point profiles also showed that
treatment with IDegLira results in more patients achieving
preprandial targets than with IDeg in DUAL II, at the exact
same dose of IDeg. This indicates the contribution of the lir-
aglutide component in reducing preprandial glucose values.
The same result was also observed in our analysis of DUAL I,
although at a lower dose of IDeg in the IDegLira arm. The
effects of the IDeg component of IDegLira on fasting glucose
levels results in a shifting of the glucose profile downward
compared to liraglutide alone, but liraglutide also contributes
the overall preprandial glucose reduction with IDegLira.
The glucose-dependent effects of liraglutide on post-
prandial glucose are maintained in IDegLira and translate to
a flattening of the blood glucose curve compared to IDeg
alone. Although not statistically significant, CGM data suggest
that IDegLira resulted in greater reductions in overall IG
fluctuation, and postprandial IG increment across all meals,
compared with IDeg. IDegLira led to a significantly greater
reduction in SMBG range over 24 h than IDeg in both trials.
This is partly explained by higher endogenous insulin
FIG. 2. Time (%) above (IG ‡9.0mmol/L), within (3.9£ IG <9.0mmol/L) and below (IG <3.9mmol/L) IG target range* for
patients in the DUAL I extension CGM sub-study. Sub-study analysis set. *IG target range: 3.9 to <9.0mmol/L. Analysis is
based on observed data using an ANCOVA method for time/duration, and a negative binomial regression model for episodes
(using a log link and the logarithm of the profile duration as offset) with treatment, region, baseline HbA1c stratum (£8.3%
[£67mmol/mol], >8.3% [>67mmol/mol]) and previous OAD treatment as fixed effects for both methods. CGM, continuous
glucose monitoring; CI, confidence interval; IG, interstitial glucose; Lira, liraglutide; SD, standard deviation.
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secretion and improved beta cell function with IDegLira.22
These results are consistent with, and extend the primary
results from, the DUAL I extension and DUAL II in which
IDegLira resulted in a lower mean EOT postprandial glucose
increment after all main meals for IDegLira versus IDeg.13,15
This analysis further confirmed that the combined effects
of IDegLira to lower (versus liraglutide) and flatten (versus
IDeg) the blood glucose curve translated into a larger pro-
portion of patients having SMBG values within the defined
target range (seeMaterials andMethods section) compared to
IDeg or liraglutide alone. This applied to the analyses of all
three postprandial values, all four preprandial values, and the
entire nine-point SMBG profile. Similarly, the CGM results
demonstrate that the time spent outside range with IDegLira
was less than with liraglutide. Although the duration of IG
<3.9 and <3.1mmol/L was not statistically significantly dif-
ferent for IDegLira and liraglutide or IDeg, the rate of IG
<3.9mmol/L with IDegLira was lower than with IDeg and
higher than with liraglutide. This latter finding is consistent
with the main DUAL I trial,14,15 which assessed episodes
(rate) of hypoglycemia rather than duration. Furthermore,
while interpretation of results for episodes of low IG during
the nocturnal period should be cautious given the low number
of episodes, a higher rate of episodes with IDegLira than with
liraglutide is also consistent with the results for nocturnal
hypoglycemia from the main DUAL I trial.15
The properties of IDeg with respect to day-to-day vari-
ability are maintained in IDegLira; day-to-day variability—
based on CGM data—was similar with all three treatments.
The data from DUAL I extension (assessed based on pre-
breakfast SMBG and CGM data, and mean IG from CGM)
showed no significant differences between IDegLira and
IDeg, and although the prebreakfast SMBG data showed
statistically significant greater variability with IDegLira than
liraglutide, this was not confirmed by the CGM data. In the
DUAL II trial the prebreakfast SMBG data indicated statis-
tically significantly lower day-to-day variability with IDe-
gLira than with IDeg. Care should be exercised in the clinical
interpretation of these data due to the inconsistency of these
results between the two trials.
Although there is debate regarding whether reducing
postprandial glucose is more important than reducing pre-
prandial glucose levels, lowering both is clearly essential if
patients are to achieve HbA1c targets.
23 Due to the comple-
mentary action of its components IDeg and the GLP-1 re-
ceptor agonist liraglutide, IDegLira allows patients with T2D
to address both fasting and postprandial glucose levels.
Lowering overall HbA1c may not be a sufficient indicator of
optimal glycemic control for every patient, and it is in-
creasingly recognized that reductions in HbA1c should also
be accompanied by reduction in glycemic fluctuations. In-
deed, large fluctuations can be masked by a ‘‘good’’ HbA1c
level, and if present, they may contribute to increased risk
of microvascular and metabolic complications, postmeal
fatigue, feelings of poor well-being, and other adverse
patient-reported outcomes associated with diabetes treat-
ments.10,11,26–29 Measures of glucose fluctuation together
with patient-reported outcomes and focus group interviews
may allow improved outcomes and potentially greater long-
term adherence to medications.
When considering the limitations of this study, it is im-
portant to remember that this was a post hoc analysis of data
generated in a clinical trial setting for a defined time period
(up to 52 weeks), with a more homogeneous population
having more regular consultations than are possible in real
world clinical practice. In the DUAL II trial, dosing of IDeg
was limited to a maximum of 50U to balance insulin exposure
between arms and isolate the contribution of the liraglutide
component of IDegLira. However, this dose restriction also
limits comparisons between IDeg treatment in DUAL II and in
real life. Also, nine-point SMBG measures are a relatively
imprecise measure of glucose fluctuations compared to CGM.
In the case of the CGM data, withdrawal of subjects, site
closure, and technical issues also meant that there was a sub-
stantial proportion of CGMdatamissing. The demographics of
patients with available data were similar to the sub-study
population (FAS), but there remains the possibility that a full
dataset would show different results. CGM data were not re-
corded in the DUAL II study,13 and comparison across the
trials is therefore not possible for the CGM endpoints. CGM
technology is rapidly improving, and although this study had
higher rates of failed sensor placement and incomplete read-
ings than desired, it still provides a valuable framework for
measuring fluctuation. The CGM findings also correlated well
with the initial glucosemanagement outcomes from the DUAL
I extension and DUAL II parent trials.13,15
From a clinical perspective, the results of this post hoc
analysis are relevant and important for both the patient and
the treating physician. First and foremost, they further refine
our understanding of how and why the additional HbA1c-
lowering benefits of IDegLira over IDeg or liraglutide alone
can be realized without increasing the risk of hypoglycemia,
compared with IDeg. This lowered risk is particularly im-
portant in real world practice, where avoidance of hypogly-
cemia is a significant safety concern for the patient, carers,
and medical providers.24,25 Reduced hypoglycemia may also
allow patients to titrate medication to achieve lower blood
glucose targets.
In conclusion, the results from these secondary analyses,
using two different methodologies to assess BG fluctuations,
consistently support the main results from the parent trials
demonstrating greater improvements in glycemic control
with IDegLira versus lira alone15 or IDeg alone.14,15 These
new findings on glycemic fluctuation provide additional
clarification about how the complementary modes of ac-
tion of IDeg and liraglutide can help more patients achieve
glycemic targets. IDegLira shifted the blood glucose profile
downward compared to liraglutide, flattened the profile
compared to IDeg, and was associated with reduced glycemic
fluctuations compared to the individual components alone,
allowing more patients to achieve their average blood glu-
cose targets while remaining within target levels for a higher
proportion of the day.
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